Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2012
Cargando información sobre las referencias
This phase II trial studies how well lenalidomide (LEN) and eltrombopag olamine (ELT) work in treating patients with symptomatic anemia in low or intermediate myelodysplastic syndrome (MDS). Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Eltrombopag olamine may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving lenalidomide and eltrombopag olamine may be an effective treatment for myelodysplastic syndrome.
Epistemonikos ID: dfe2281d60bd11610bb800923d2c886565ec0dcc
First added on: May 11, 2024